Last reviewed · How we verify

NCT05864430

Effıcıency of Sexual and Reproductıve Health Educatıon

Completed NA Last updated 18 May 2023
What this trial tests

NA trial testing Face-to-face Training Group in Reproductive Health in 165 participants. Completed in 30 December 2022.

Timeline
15 May 2022
Primary endpoint
30 September 2022
30 December 2022

Quick facts

Lead sponsorMarmara University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment165
Start date15 May 2022
Primary completion30 September 2022
Estimated completion30 December 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Marmara University

Who can join

Adults 18 to 49, any sex, with Reproductive Health or Sexual Health. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The youth period is a period when information and education are important. Reproductive and sexual health problems have an important place in aging health problems in youth (Gölbaşlı 2003). All over the world, STIs are most common in the 20-24 age group, followed by the 15-19 and 25-29 age groups. STIs are the most common disease in many countries, especially among young people between the ages of 15-29 (Topbaş et al. 2003). STIs, which are one of the factors that negatively affect public health; are infections transmitted from person to person through sexual contact. According to WHO estimates, approximately 350 million people suffer from curable STIs each year, and the incidence and prevalence of STIs among young people in developed and developing countries are increasing. Although young adults are generally at risk, STIs are most common in people aged 15-49. They have a very important place in terms of human health because they are frequently seen, difficult to diagnose, and cause serious complications when not treated. Incomplete and incorrect information among people who start sexual intercourse at an early age causes difficulties in the prevention of these diseases (Özalp et al. 2012). Having sexual intercourse at an early age, being polygamous, having special sexual preferences, being with or having sex with those who have paid for sexual intercourse, and not using condoms are among the risk factors for STIs (Siyez 2009). We can say that the age period in which STIs are common is parallel to sexual activity. In addition to various socio-demographic factors, it is likely that the most provoking issue in this period is the lack of knowledge of young people (Karaköse and Aydın 2011). In the STD guide published by the CDC, it is recommended to evaluate the people who constitute the risk group in the prevention of these diseases and to provide education and counseling (CDC, 2020). In this context, training to increase the level of knowledge and awareness of young people, who are one of the high-risk groups in society in terms of STD, is important in terms of reducing risky sexual behaviors, early diagnosis, and treatment. Based on all these reasons; It is aimed to evaluate the effectiveness of sexual and reproductive health education given to university students.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evaluation of the Effectiveness of Sexual and Reproductive Health Education Given to University Students: A Randomized Controlled Trial.
    Öz T, Arslan Tarus H, Ölmez Yalazı R, Demirci N. · · 2025 · PMID 40400558 · DOI 10.1080/19317611.2025.2486105

Verify or expand the search:

Other recruiting trials for Reproductive Health

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05864430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing